Immunology of anti-phospholipid antibodies and cofactors

Tatsuya Atsumi, Eiji Matsuura, Takao Koike

Research output: Chapter in Book/Report/Conference proceedingChapter

9 Citations (Scopus)

Abstract

Anti-phospholipid antibodies (aPLs) are present in a wide range of infectious and autoimmune diseases. aPLs, in particular anti-cardiolipin antibodies (aCL) and lupus anticoagulants (LA), are of considerable clinical importance because of the close association with predominant clinical features of venous, arterial thrombosis, and pregnancy morbidity. The term "antiphospholipid syndrome (APS)" has been used to define this set of pathologic features. Numerous studies have elucidated the specificity of anti-phospholipid antibodies (aPLs). It is clear that the nomenclature of aPLs is a misnomer and that these autoantibodies react with phospholipid-binding plasma proteins (cofactors), such as β2-glycoprotein, prothrombin, annexin V, high-molecular-weight kininogen, protein S, and protein C. Many varieties of pathophysiologic mechanisms have been explored in order to understand the wide spectrum of antigenic specificities of aPLs. Numerous observations are reviewed in this discussion concerning putative mechanisms related to anti-β2-GPI antibodies or other aPLs predisposing to thrombosis and to atherosclerosis.

Original languageEnglish
Title of host publicationSystemic Lupus Erythematosus: Fourth Edition
PublisherElsevier Inc.
Pages1081-1105
Number of pages25
ISBN (Print)9780124339019
DOIs
Publication statusPublished - May 2004

Fingerprint

Allergy and Immunology
Anti-Idiotypic Antibodies
Phospholipids
High Molecular Weight Kininogens
Lupus Coagulation Inhibitor
Cardiolipins
Antiphospholipid Syndrome
Annexin A5
Protein S
Prothrombin
Protein C
Terminology
Venous Thrombosis
Autoantibodies
Autoimmune Diseases
Communicable Diseases
Blood Proteins
Epitopes
Atherosclerosis
Glycoproteins

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Atsumi, T., Matsuura, E., & Koike, T. (2004). Immunology of anti-phospholipid antibodies and cofactors. In Systemic Lupus Erythematosus: Fourth Edition (pp. 1081-1105). Elsevier Inc.. https://doi.org/10.1016/B978-012433901-9/50042-9

Immunology of anti-phospholipid antibodies and cofactors. / Atsumi, Tatsuya; Matsuura, Eiji; Koike, Takao.

Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc., 2004. p. 1081-1105.

Research output: Chapter in Book/Report/Conference proceedingChapter

Atsumi, T, Matsuura, E & Koike, T 2004, Immunology of anti-phospholipid antibodies and cofactors. in Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc., pp. 1081-1105. https://doi.org/10.1016/B978-012433901-9/50042-9
Atsumi T, Matsuura E, Koike T. Immunology of anti-phospholipid antibodies and cofactors. In Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc. 2004. p. 1081-1105 https://doi.org/10.1016/B978-012433901-9/50042-9
Atsumi, Tatsuya ; Matsuura, Eiji ; Koike, Takao. / Immunology of anti-phospholipid antibodies and cofactors. Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc., 2004. pp. 1081-1105
@inbook{01756a2a2280447cacf2ff081d5e7763,
title = "Immunology of anti-phospholipid antibodies and cofactors",
abstract = "Anti-phospholipid antibodies (aPLs) are present in a wide range of infectious and autoimmune diseases. aPLs, in particular anti-cardiolipin antibodies (aCL) and lupus anticoagulants (LA), are of considerable clinical importance because of the close association with predominant clinical features of venous, arterial thrombosis, and pregnancy morbidity. The term {"}antiphospholipid syndrome (APS){"} has been used to define this set of pathologic features. Numerous studies have elucidated the specificity of anti-phospholipid antibodies (aPLs). It is clear that the nomenclature of aPLs is a misnomer and that these autoantibodies react with phospholipid-binding plasma proteins (cofactors), such as β2-glycoprotein, prothrombin, annexin V, high-molecular-weight kininogen, protein S, and protein C. Many varieties of pathophysiologic mechanisms have been explored in order to understand the wide spectrum of antigenic specificities of aPLs. Numerous observations are reviewed in this discussion concerning putative mechanisms related to anti-β2-GPI antibodies or other aPLs predisposing to thrombosis and to atherosclerosis.",
author = "Tatsuya Atsumi and Eiji Matsuura and Takao Koike",
year = "2004",
month = "5",
doi = "10.1016/B978-012433901-9/50042-9",
language = "English",
isbn = "9780124339019",
pages = "1081--1105",
booktitle = "Systemic Lupus Erythematosus: Fourth Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Immunology of anti-phospholipid antibodies and cofactors

AU - Atsumi, Tatsuya

AU - Matsuura, Eiji

AU - Koike, Takao

PY - 2004/5

Y1 - 2004/5

N2 - Anti-phospholipid antibodies (aPLs) are present in a wide range of infectious and autoimmune diseases. aPLs, in particular anti-cardiolipin antibodies (aCL) and lupus anticoagulants (LA), are of considerable clinical importance because of the close association with predominant clinical features of venous, arterial thrombosis, and pregnancy morbidity. The term "antiphospholipid syndrome (APS)" has been used to define this set of pathologic features. Numerous studies have elucidated the specificity of anti-phospholipid antibodies (aPLs). It is clear that the nomenclature of aPLs is a misnomer and that these autoantibodies react with phospholipid-binding plasma proteins (cofactors), such as β2-glycoprotein, prothrombin, annexin V, high-molecular-weight kininogen, protein S, and protein C. Many varieties of pathophysiologic mechanisms have been explored in order to understand the wide spectrum of antigenic specificities of aPLs. Numerous observations are reviewed in this discussion concerning putative mechanisms related to anti-β2-GPI antibodies or other aPLs predisposing to thrombosis and to atherosclerosis.

AB - Anti-phospholipid antibodies (aPLs) are present in a wide range of infectious and autoimmune diseases. aPLs, in particular anti-cardiolipin antibodies (aCL) and lupus anticoagulants (LA), are of considerable clinical importance because of the close association with predominant clinical features of venous, arterial thrombosis, and pregnancy morbidity. The term "antiphospholipid syndrome (APS)" has been used to define this set of pathologic features. Numerous studies have elucidated the specificity of anti-phospholipid antibodies (aPLs). It is clear that the nomenclature of aPLs is a misnomer and that these autoantibodies react with phospholipid-binding plasma proteins (cofactors), such as β2-glycoprotein, prothrombin, annexin V, high-molecular-weight kininogen, protein S, and protein C. Many varieties of pathophysiologic mechanisms have been explored in order to understand the wide spectrum of antigenic specificities of aPLs. Numerous observations are reviewed in this discussion concerning putative mechanisms related to anti-β2-GPI antibodies or other aPLs predisposing to thrombosis and to atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=8344236700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8344236700&partnerID=8YFLogxK

U2 - 10.1016/B978-012433901-9/50042-9

DO - 10.1016/B978-012433901-9/50042-9

M3 - Chapter

AN - SCOPUS:8344236700

SN - 9780124339019

SP - 1081

EP - 1105

BT - Systemic Lupus Erythematosus: Fourth Edition

PB - Elsevier Inc.

ER -